Advances in immunotherapy for gynecological malignancies.
Gynecological malignancies
Immune checkpoint inhibitor
Immunotherapy
Tumor vaccine
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
11
02
2023
revised:
21
05
2023
accepted:
25
06
2023
medline:
27
7
2023
pubmed:
30
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
To date, surgery, chemotherapy and radiotherapy are mainly used to treat or remove gynecological malignancies. However, these approaches have their limitations when facing complicated female diseases such as advanced cervical and endometrial cancer (EC), chemotherapy-resistant gestational trophoblastic neoplasia and platinum-resistant ovarian cancer. Instead, immunotherapy, as an alternative, could significantly improve prognosis of those patients receiving traditional treatments, with better antitumor activities and possibly less cellular toxicities. Its' development is still not fast enough to meet the current clinical needs. More preclinical studies and larger-scale clinical trials are required. This review aims to introduce the landscape and up-to-date status of immunotherapy against gynecological malignancies, with a discussion of the challenges and future direction.
Identifiants
pubmed: 37385307
pii: S1040-8428(23)00151-8
doi: 10.1016/j.critrevonc.2023.104063
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104063Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no conflict of interest.